Dataset from An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' COPD Vaccine (GSK3277511A) in Adults

The purpose of this study is to test two different vaccine schedules to be used for
administering the investigational NTHi Mcat vaccine that will be targeting patients with
chronic obstructive pulmonary disease (COPD) to prevent acute exacerbations. An acute
exacerbation is when the breathlessness in COPD patients will get even worse than it normally
already is, sometimes to the point where oxygen therapy is required.

In previous studies, study participants have received two doses of the vaccine according to a
0, 2 month vaccination schedule, in addition to standard care. The current study will find
out if a third dose of the study vaccine against NTHi/Mcat is safe and working well. The
study will also investigate if the third dose of vaccine works best when given after 6 months
or after 12 months.